Afficher la notice abrégée

Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study

dc.rights.licenseopenen_US
dc.contributor.authorLAM, Marion
dc.contributor.authorTOUITOU, Valerie
dc.contributor.authorCHOQUET, Sylvain
dc.contributor.authorCASSOUX, Nathalie
dc.contributor.authorGHESQUIERES, Herve
dc.contributor.authorKODJIKIAN, Laurent
dc.contributor.authorSCHMITT, Anna
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGATTOUSSI, Sarra
dc.contributor.authorTABOURET, Emeline
dc.contributor.authorSAMPO, Magali
dc.contributor.authorBLONSKI, Marie
dc.contributor.authorANGIOI-DUPREZ, Karine
dc.contributor.authorHOUOT, Roch
dc.contributor.authorMOURIAUX, Frederic
dc.contributor.authorGYAN, Emmanuel
dc.contributor.authorLE LEZ, Marie-Laure
dc.contributor.authorMOLES, Marie-Pierre
dc.contributor.authorCROISE, Fabien
dc.contributor.authorCHAUCHET, Adrien
dc.contributor.authorSCHWARTZ, Claire
dc.contributor.authorAHLE, Guido
dc.contributor.authorMEYER, Laurent
dc.contributor.authorGRESSIN, Remy
dc.contributor.authorCHIQUET, Christophe
dc.contributor.authorOBERIC, Lucie
dc.contributor.authorOLLE, Priscille
dc.contributor.authorMAROLLEAU, Jean-Pierre
dc.contributor.authorJANY, Benjamin
dc.contributor.authorTEMPESCUL, Adrian
dc.contributor.authorCOCHENER, Beatrice
dc.contributor.authorDAMAJ, Gandhi
dc.contributor.authorQUINTYN, Jean-Claude
dc.contributor.authorMOLUCON-CHABROT, Cecile
dc.contributor.authorROUSSEAU, Eve
dc.contributor.authorFRANCIANE, Paul
dc.contributor.authorSCHNEIDER, Christelle
dc.contributor.authorMASSE, Helene
dc.contributor.authorTAMBURINI-BONNEFOY, Jerome
dc.contributor.authorBREZIN, Antoine
dc.contributor.authorFORNECKER, Luc-Matthieu
dc.contributor.authorBALLONZOLI, Laurent
dc.contributor.authorLE GARFF-TAVERNIER, Magali
dc.contributor.authorHOANG-XUAN, Khe
dc.contributor.authorBODAGHI, Bahram
dc.contributor.authorSOUSSAIN, Carole
dc.contributor.authorHOUILLIER, Caroline
dc.date.accessioned2021-06-29T09:22:46Z
dc.date.available2021-06-29T09:22:46Z
dc.date.issued2021-04-17
dc.identifier.issn0361-8609en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/79315
dc.description.abstractEnThe treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high-dose methotrexate (IV HD-MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first-line treatment with HD-MTX between 2011-2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL-10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL-10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow-up of 61 months, 41/59 (69%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression-free survival, ocular-free survival and brain-free survival were 75, 18, 29 and 73 months, respectively. IV HD-MTX based systemic therapy as a first-line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL-10. This article is protected by copyright. All rights reserved.
dc.language.isoENen_US
dc.title.enIntravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/ajh.26199en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33864703en_US
bordeaux.journalAmerican Journal of Hematologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=American%20Journal%20of%20Hematology&rft.date=2021-04-17&rft.eissn=0361-8609&rft.issn=0361-8609&rft.au=LAM,%20Marion&TOUITOU,%20Valerie&CHOQUET,%20Sylvain&CASSOUX,%20Nathalie&GHESQUIERES,%20Herve&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée